Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/11/2010

QUITYCurrent liabilities:Current portion of long-term debt

$   2,666,668$
9,061,973Current portion of other long-term obligations

12,035144,828Accounts payable

3,416,3705,632,796Other accrued liabilities

3,817,8223,784,777Total current liabilities

9,912,89518,624,374Revolving line of credit

1,825,9511,825,951Long-term debt, excluding current portion

3,333,3328,938,027Other long-term obligations, excluding current portion

211,757184,632Total liabilities

15,283,93529,572,984Commitments and contingenciesRedeemable common stock

-1,930,000Equity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;20,353,849 and 20,180,486(1) shares issued and outstandingas of September 30, 2010 and December 31, 2009, respectively

68,521,47067,711,746Retained earnings

6,161,2524,542,126Total shareholders' equity

74,682,72272,253,872Noncontrolling interests

(56,791)(32,536)Total equity

74,625,93172,221,336Total liabilities and equity

$ 89,909,866$  103,724,320(1) Number of shares issued and outstanding represent total shares of common stock regardless of classification on the consolidated balance sheet. The number of shares of redeemable common stock at December 31, 2009 was 142,016.CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Income
(Unaudited)Three months ended September 30,Nine months ended September 30,2010200920102009Net revenues

$
2,190,870$
3,597,760$
33,061,457$
32,822,972Costs and expenses:Cost of products sold

909,4341,761,0692,632,4473,271,363Selling and marketing

5,692,0486,087,80717,147,68314,611,796Research and development

1,138,955640,8772,947,6234,041,719General and administrative

1,806,9752,537,6275,471,0125,218,925Amortization of productlicense right

171,732171,726515,184515,178Other

27,86926,59583,283
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
3. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
4. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
5. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
6. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
7. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
8. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
9. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
10. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market ... 2014 LeadingAge Annual Meeting in Nashville, TN. ... System, the market leading solution for onsite, remote medication ... term care facilities to safely and securely dispense medication ... to first dose, helps ensure that the correct medication ...
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
(Date:10/17/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... the company,s award-winning, leadership development and cultural orientation ... from around the globe were in attendance for ... is a two-day one-of-a-kind experience for new and ...
Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2Ameritox Appoints New Chief Medical Officer 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
... Naurex Inc., a clinical-stage company developing innovative ... today announced that it has initiated a Phase II ... Glycine-site Functional Partial Agonist (GFPA) selective modulator of the ... therapy for patients who are not achieving an adequate ...
... 2011 Cempra Pharmaceuticals Inc. today announced that ... present at the 2011 Wells Fargo Healthcare Conference at ... Fernandes will provide an overview of the company,s two ... and other infections and TAKSTA™ for the oral treatment ...
Cached Medicine Technology:Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... gave physicians seemingly miraculous weapons against infectious disease. ... and tuberculosis were suddenly at hand. Moreover, many ... versatile enough to knock out a wide range ... a fundamental limitation: They,re useless against viruses, which ...
... team from the National Taiwan University Hospital has evaluated ... models severely damaged by two kinds of chemical toxicity ... to efficiently repopulate the toxin-induced, severely damaged livers. The ... double issue of Cell Transplantation (18:10/11) and ...
... Surgeons who engage in minimally invasive, laparoscopic surgery are ... their own detriment. That,s the finding of the largest ... perform laparoscopic procedures. The survey, developed at the University ... 87 percent of laparoscopic surgeons have experienced physical symptoms ...
... ... Integration and Strong Business Intelligence Allows for Real-Time Monitoring and Better Decision Making ... ... integration and interoperability solutions, announced today it has entered a strategic partnership agreement ...
... ... of managed network services to help regional SMBs build a solid IT foundation to ... ... provider of managed IT services for Texas-based small- and medium-sized businesses, today ...
... , , , , BEIJING , ... or the "Company"), a leading China -based vaccine manufacturer,announced today ... exercised in full their option to purchase an,additional 1,500,000 common shares ... and sell a total of 11,500,000 common shares,at $5.75 ...
Cached Medicine News:Health News:Compound found that targets wide range of viruses 2Health News:Beyond liver transplants: Acutely damaged livers may be repaired via transplanted hepatocytes 2Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 2Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 3Health News:Survey finds many surgeons suffer injuries from minimally invasive techniques 4Health News:BridgeGate and Information Builders form Strategic Partnership to Extend Integration Capability for Healthcare and Government Markets 2Health News:BridgeGate and Information Builders form Strategic Partnership to Extend Integration Capability for Healthcare and Government Markets 3Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 2Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 3Health News:Sinovac Announces Exercise of Over-Allotment Option 2Health News:Sinovac Announces Exercise of Over-Allotment Option 3
Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
LB Agar plates with 10mM Magnesium Sulfate....
LB Agar plates with 0.1mM EDTA....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Medicine Products: